Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | An insight into how novel agents are influencing survival outcomes in patients with MF

Lucia Masarova • 26 Aug 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Momelotinib Pacritinib Ruxolitinib
COMFORT-I COMFORT-II SIMPLIFY-1 SIMPLIFY-2

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on survival outcomes in patients with myelofibrosis (MF) and how novel agents, such as JAK inhibitors, have improved patient quality of life and symptoms. Dr Masarova also explains the challenges with directly assessing survival outcomes and the need to obtain more detailed data from clinical trials. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Lucia Masarova

1:19
What's on the horizon for the treatment of MPNs?
Lucia Masarova • 9 Dec 2023
2:13
Splicing mutations in post-ET/post-PV myelofibrosis
Lucia Masarova • 9 Dec 2023
3:17
Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1
Lucia Masarova • 9 Dec 2023
3:18
Cladribine-based chemotherapy for patients with secondary AML arising after MPNs
Lucia Masarova • 9 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals